Archived Bulletins

June 06, 2018

Study results suggest that a new pancreatic cancer treatment become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery. The randomized phase III clinical trial was sponsored by the academic cancer research groups of UNICANCER, in Paris, France and the Canadian Cancer Trials Group (CCTG). The results show that the risk of cancer recurring in post-operative pancreatic cancer patients was reduced by almost 50% with the mFOLFIRINOX chemotherapy combination.

Read More

Published: June 06, 2018
Category: News

Bladder cancer hit the world stage with an oral presentation at ASCO this past weekend. The presentation of the results of the study was given by Dr. Srikala Sridhar, BL12 Study Chair, at the general meeting in Chicago. Bladder cancer is the 5th most common cancer in Canada with 9000 new cases annually. For patients with advanced disease who progress on first line chemotherapy, options include immunotherapy or taxane-based chemotherapy. 

Read More

May 23, 2018

Published: May 23, 2018
Category: Trials

500 Patients randomized on the SHAPE study!

Congratulations to Dr. Dounia Skalli and the team at centre hospitalier intercommunal de Créteil, France for enrolling the 500th patient to the SHAPE study! On behalf of the SHAPE trial committee, we would like to thank you for your tremendous and unwavering support of our trial.

Read More

The Sunnybrook Health Sciences Centre and the Ottawa Hospital are currently enrolling women in the Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare conventional mammography (2-D) to the newer digital tomosynthesis method (3-D).The large scale North American study was developed by the US based ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and the National Cancer Institute (NCI), with the Canadian Cancer Trials Group (CCTG) coordinating the trial in Canada (more national sites will be opening the trial over the next several months).

Read More

Published: May 23, 2018
Category: Publications

Citation for a MA27 publication

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).

Read More

May 09, 2018

Published: May 09, 2018
Category:
On behalf of the CRA Executive Committee, we hope that those of you who were able to attend the CRA session at Spring Meeting this year found it informative. For those interested, we have posted the presentations to the CRA page under "Spring Meeting of Participants" here: https://www.ctg.queensu.ca/private/cra/clinical-research-associates-committee
 
Presentations include:
  • Central Office policy updates
Read More

Published: May 09, 2018
Category:
MA.27 (NCT00066573) - A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer publication:
 
Ho MF, Lummertz da Rocha E, Zhang C, Ingle J, Goss P, Shepherd L, Kubo M, Wang L, Li H, Weinshilboum R. TCL1A, a novel transcription factor and a co-regulator of NF-kB p65: SNP and estrogen-dependence (ONLINE). J Pharmacol Exp Ther 2018.
Read More

April 23, 2018

Published: April 23, 2018
Category: Trials

NEC 2 ( NCT01229943) Randomized Phase II Study of Everolimus Alone versus Everolimus Plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours has been permanently closed by the lead group.

About the trial

Read More